ClinicalTrials.gg
CompletedNCT04138043Updated May 24, 2021Results posted

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants

A Phase 1 interventional study of Placebo and GSK2330811 in Healthy Volunteers, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-24.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This is a randomized, double-blind (sponsor-open), placebo-controlled, single-center study involving Japanese participants. The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity after a single subcutaneous (SC) dose of GSK2330811 in healthy Japanese participants. GSK2330811 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that binds and inhibits the action of Oncostatin M (OSM) and is being developed for the treatment of Crohn's disease (CD) and Systemic sclerosis (SSc). Participants will be randomized to receive either GSK2330811 (450 milligram [mg]) or placebo in an approximate ratio of 7:3.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • GSK2330811
  • Healthy participants
  • Japanese
  • Pharmacokinetics
  • Safety
  • Subcutaneous dose
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 65 years of age inclusive, at the time of signing the .
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests and 12-lead ECGs.
  • A participant with a clinical abnormality or laboratory parameters outside the reference range for the healthy population being studied that is not specifically listed in the inclusion or exclusion criteria may be included if the investigator and sponsor medical monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures or interpretation.
  • Participants with body weight >=45 kilogram (kg) and (BMI) within the range 18.5-29.9 kg per square meter.
  • Male participants.
  • Participants capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Participants with Japanese ancestry, defined as having been born in Japan, being descendants of four ethnic Japanese grandparents and two ethnic Japanese parents, holding a Japanese passport or identity papers, and being able to speak Japanese. Participants should have lived outside Japan for less than 10 years at the time of screening.

Exclusion criteria

Exclusion Criteria:

  • Participants with sensitivity to any of the study treatments or components there of (including humanized monoclonal antibodies) or history of severe post treatment reactions including erythema multiforme major, linear immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis and exfoliative dermatitis.
  • Participants with any other history of significant allergy that in the opinion of the investigator contraindicates their participation in this study.
  • Participants with an active infection or a history of serious infections as follows: Use of antimicrobials (antibacterials, antivirals, antifungals or antiparasitic agents) for an infection within 30 days prior to Day 1. Topical treatments may be allowed at the Investigator's discretion (in consultation with the Medical Monitor); A history of opportunistic or recurrent infections, as determined by the investigator; Currently active or unresolved infection (participants with 'trivial' infections such as tinea pedis may be eligible at the discretion of the investigator); Symptomatic herpes zoster within 3 months prior to screening; History of tuberculosis (TB) (active or latent) irrespective of treatment status; and a positive diagnostic TB test at screening (defined as a positive QuantiFERON test).
  • Participants with any planned major surgical procedure during the study.
  • Participants with a history of hematological disease, for example (but not limited to): significant anemia, disorders including drug-induced thrombocytopenia or primary immune thrombocytopenia and coagulation disorders including von Willebrand's disease.
  • Participants with a history of carcinoma in situ and malignant disease, with the exception of adequately treated non- basal or squamous cell cancer of the skin that has been fully treated and shows no evidence of recurrence after 3 years.
  • Participants with >450 millisecond (msec) at screening.
  • Participants with use of prescription or non-prescription drugs (including recreational drugs and herbal medications) within 7 days or 5 half-lives (whichever is longer) prior to Day 1 unless in the opinion of the investigator (in consultation with the sponsor medical monitor) the medication will not interfere with the study or compromise participant safety. Paracetamol at doses of \<=4 grams per day, and occasional use of non-steroidal anti-inflammatory drugs (NSAIDs) at licensed doses, are permitted.
  • Participants who received within 4 weeks prior to Day 1, or any plan to receive a live vaccination during the study (up to and including to the last follow-up visit).
  • Participation in a clinical trial and has received an medicine product (IMP) within the following time period prior to Day 1: 3 months, 5 half-lives, or twice the duration of the biological effect of the IMP (whichever is longer).
  • Participants with exposure to more than 4 new chemical entities within 12 months prior to Day 1.
  • Participation in the study would result in loss of blood or blood products in excess of 500 milliliter (mL) within 3 months.
  • Participants with platelet count or below the normal range at any time during screening.
  • Participants with (ALT) >1.5 times (ULN) at any time during screening.
  • Participants with >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent) at any time during screening.
  • Participants with presence of surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), or positive virus (HCV) antibody result at screening. Participants with positive HCV antibody due to prior resolved disease can be enrolled only if a confirmatory negative HCV Ribonucleic acid (RNA) test is obtained.
  • Participants with positive (HIV) antibody test at screening.
  • Participants with positive pre-study drug or alcohol screen.
  • Participants with history of regular alcohol consumption within 6 months of the screening visit in excess of an average weekly intake of >21 units. One unit is equivalent to 8 gram of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
  • Participants planning to travel to regions of high endemic infection, as determined by the investigator, for the duration of the study.
  • Participants with unstable lifestyle factors, to the extent that in the opinion of the investigator they would interfere with the ability of a participant to complete the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    GSK2330811 450 mg

    Participants will receive a single 450 mg SC dose of GSK2330811, administered as three separate SC injections of 150 milligrams per milliliter \[mg/mL\]).

    Drug: GSK2330811

  • Placebo comparator
    Placebo

    Participants will receive GSK2330811 matching placebo administered as three separate SC injections.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.

  • GSK2330811 will be available as SC injection 150 mg/mL.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment. Safety Population consisted of all randomized participants who received at least one dose of study treatment.

    Time frame: Up to Day 126

  2. Number of Participants With Worst Case Vital Sign Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline

    Vital signs were measured in semi-supine position after 5 minutes of rest and included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR). Participants were counted in the worst case category that their value changed to low, within range or high, unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the "Within Range or No Change" category. Participants were counted twice if values changed 'To Low' and 'To High', so the percentages were not added up to 100 percent (%). Participants with missing Baseline values were assumed as within range value. PCI ranges were: SBP (lower: \<85, upper: \>160 millimeter of mercury \[mmHg\]); DBP (lower: \<45, upper: \>100 mmHg); HR (lower: \<40, upper: \>110 beats per minute). Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment.

    Time frame: Baseline (Pre-dose, Day 1) and up to Day 126

  3. Change From Baseline in Body Temperature

    Body temperature was measured in semi-supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Pre-dose, Day 1), Day 1: 1, 4, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

  4. Number of Participants With Worst Case Abnormal Electrocardiogram (ECG) Findings

    12-lead ECGs were recorded in semi-supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal laboratory findings were those which were not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

    Time frame: Up to Day 126

  5. Number of Participants With Maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or Higher Clinical Chemistry Parameters

    Blood samples were collected for the analysis of clinical chemistry parameters. Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling. Higher grade indicates more severity. Clinical chemistry parameters included: total bilirubin, calcium, creatinine and triglycerides.

    Time frame: Up to Day 126

  6. Number of Participants With Grade Increase Post-Baseline Relative to Baseline in Hematology Parameters

    Blood samples were collected for the analysis of the following hematology parameters: hemoglobin (Hb), lymphocytes (Lympho), platelet count (PC), neutrophil count (Neutro) and White Blood Cell count (WBC). The laboratory parameters were graded according to NCI-CTCAE version 5.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates more severity. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. An increase was defined as an increase in CTCAE Grade relative to Baseline Grade.

    Time frame: Baseline (Pre-dose, Day 1) and up to Day 126

  7. Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline

    Urine samples were collected for analysis of blood, glucose, ketones and protein by a dipstick method. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, protein, blood and ketones can be read as negative (-), trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. Any increase means any increase to trace, 1+, 2+ or 3+ post-Baseline relative to Baseline. Number of participants with worst case any increase in urinalysis results post-Baseline relative to Baseline has been presented.

    Time frame: Baseline (Pre-dose, Day 1) and up to Day 126

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) for GSK2330811

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis. Pharmacokinetic Population consisted of all participants in the Safety population who received at least one active dose of study treatment and had at least 1 non-missing PK assessment.

    Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

  2. Area Under the Plasma Concentration Time-curve From Time Zero to Infinity (AUC[0-infinity]) for GSK2330811

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

  3. Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2330811

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

  4. Apparent Systemic Clearance (CL/F) for GSK2330811

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

  5. Time to Cmax (Tmax) for GSK2330811

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

  6. Terminal Half-life (t1/2) for GSK2330811

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

  7. Apparent Volume of Distribution at Steady State (Vss/F) for GSK2330811

    Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

    Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

  8. Number of Participants With Positive Anti-GSK2330811 Antibodies

    Serum samples were analyzed for the presence of anti-GSK2330811 antibodies using an antibody binding assay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Number of participants with confirmed positive anti-GSK2330811 antibodies are presented.

    Time frame: Up to Day 126

  9. Platelet Count Nadir for GSK2330811

    Blood samples were collected at indicated time points for analysis of platelet count nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the platelet count.

    Time frame: Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

  10. Time to Platelet Count Nadir for GSK2330811

    Blood samples were collected at indicated time points for analysis of platelet count nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the platelet count. Time to nadir was defined as Study Day of Nadir minus 1.

    Time frame: Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

  11. Hemoglobin Nadir for GSK2330811

    Blood samples were collected at the indicated time points for analysis of hemoglobin nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the hemoglobin.

    Time frame: Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

  12. Time to Hemoglobin Nadir for GSK2330811

    Blood samples were collected at indicated time points for analysis of hemoglobin nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the hemoglobin. Time to nadir was defined as Study Day of Nadir minus 1.

    Time frame: Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126

07

Results

Posted May 24, 2021

Participant flow

This was a randomized, double-blind, placebo-controlled, single-center study with single subcutaneous (SC) dose of GSK2330811 administered in healthy male Japanese participants.

Participant flow — Overall Study
MilestonePlaceboGSK2330811 450 mg
Started27
Completed26
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment. Safety Population consisted of all randomized participants who received at least one dose of study treatment.

Time frame:
Up to Day 126
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboGSK2330811 450 mg
AEs26
SAEs00
PrimaryNumber of Participants With Worst Case Vital Sign Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline

Vital signs were measured in semi-supine position after 5 minutes of rest and included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR). Participants were counted in the worst case category that their value changed to low, within range or high, unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the "Within Range or No Change" category. Participants were counted twice if values changed 'To Low' and 'To High', so the percentages were not added up to 100 percent (%). Participants with missing Baseline values were assumed as within range value. PCI ranges were: SBP (lower: \<85, upper: \>160 millimeter of mercury \[mmHg\]); DBP (lower: \<45, upper: \>100 mmHg); HR (lower: \<40, upper: \>110 beats per minute). Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment.

Time frame:
Baseline (Pre-dose, Day 1) and up to Day 126
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Vital Sign Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline
ParticipantsPlaceboGSK2330811 450 mg
SBP, To low00
SBP, To Within Range or No Change27
SBP, To high00
DBP, To low00
DBP, To Within Range or No Change27
DBP, To high00
HR, To low00
HR, To Within Range or No Change27
HR, To high00
PrimaryChange From Baseline in Body Temperature

Body temperature was measured in semi-supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Pre-dose, Day 1), Day 1: 1, 4, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Mean · Degrees Celsius
Change From Baseline in Body Temperature
Degrees CelsiusPlaceboGSK2330811 450 mg
Day 1: 1 hour, n=2,70.15 ± 0.2120.06 ± 0.237
Day 1: 4 hour, n=2,70.40 ± 0.2830.07 ± 0.287
Day 1: 8 hour, n=2,70.45 ± 0.0710.40 ± 0.346
Day 2: n=2,7-0.15 ± 0.919-0.03 ± 0.486
Day 3: n=2,7-0.30 ± 0.283-0.34 ± 0.336
Day 5: n=2,70.20 ± 0.424-0.06 ± 0.800
Day 7: n=2,7-0.30 ± 0.5660.09 ± 0.521
Day 10: n=2,7-0.10 ± 0.283-0.10 ± 0.862
Day 14: n=2,70.25 ± 0.4950.21 ± 0.537
Day 21: n=2,70.05 ± 0.2120.09 ± 0.609
Day 28: n=2,70.20 ± 0.424-0.06 ± 0.670
Day 42: n=2,7-0.60 ± 0.283-0.10 ± 0.695
Day 56: n=2,60.00 ± 0.141-0.03 ± 0.715
Day 84: n=1,60.90 ± NA0.30 ± 0.494
Day 126: n=0,6—0.28 ± 0.595
PrimaryNumber of Participants With Worst Case Abnormal Electrocardiogram (ECG) Findings

12-lead ECGs were recorded in semi-supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal laboratory findings were those which were not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame:
Up to Day 126
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Abnormal Electrocardiogram (ECG) Findings
ParticipantsPlaceboGSK2330811 450 mg
Abnormal - not clinically significant01
Abnormal - clinically significant00
PrimaryNumber of Participants With Maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or Higher Clinical Chemistry Parameters

Blood samples were collected for the analysis of clinical chemistry parameters. Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling. Higher grade indicates more severity. Clinical chemistry parameters included: total bilirubin, calcium, creatinine and triglycerides.

Time frame:
Up to Day 126
Reported as:
Count of participants · Participants
Number of Participants With Maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or Higher Clinical Chemistry Parameters
ParticipantsPlaceboGSK2330811 450 mg
Total Bilirubin, Grade 101
Total Bilirubin, Grade 200
Total Bilirubin, Grade 300
Total Bilirubin, Grade 400
Calcium, Grade 125
Calcium, Grade 200
Calcium, Grade 300
Calcium, Grade 400
Creatinine, Grade 101
Creatinine, Grade 200
Creatinine, Grade 300
Creatinine, Grade 400
Triglycerides, Grade 101
Triglycerides, Grade 200
Triglycerides, Grade 300
Triglycerides, Grade 400
PrimaryNumber of Participants With Grade Increase Post-Baseline Relative to Baseline in Hematology Parameters

Blood samples were collected for the analysis of the following hematology parameters: hemoglobin (Hb), lymphocytes (Lympho), platelet count (PC), neutrophil count (Neutro) and White Blood Cell count (WBC). The laboratory parameters were graded according to NCI-CTCAE version 5.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates more severity. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. An increase was defined as an increase in CTCAE Grade relative to Baseline Grade.

Time frame:
Baseline (Pre-dose, Day 1) and up to Day 126
Reported as:
Count of participants · Participants
Number of Participants With Grade Increase Post-Baseline Relative to Baseline in Hematology Parameters
ParticipantsPlaceboGSK2330811 450 mg
Hb, Anemia, increase to Grade 100
Hb, Anemia, increase to Grade 200
Hb, Anemia, increase to Grade 300
Hb, Anemia, increase to Grade 400
Hb, Hb increased, increase to Grade 100
Hb, Hb increased, increase to Grade 200
Hb, Hb increased, increase to Grade 300
Hb, Hb increased, increase to Grade 400
Lympho,Lympho count decreased, increase to Grade 103
Lympho,Lympho count decreased, increase to Grade 210
Lympho,Lympho count decreased, increase to Grade 300
Lympho,Lympho count decreased, increase to Grade 400
Lympho,Lympho count increased, increase to Grade 100
Lympho,Lympho count increased, increase to Grade 200
Lympho,Lympho count increased, increase to Grade 300
Lympho,Lympho count increased, increase to Grade 400
PC, PC decreased,increase to Grade 103
PC, PC decreased,increase to Grade 202
PC, PC decreased,increase to Grade 301
PC, PC decreased,increase to Grade 400
Neutro,Neutro count decreased,increase to Grade 100
Neutro,Neutro count decreased,increase to Grade 201
Neutro,Neutro count decreased,increase to Grade 300
Neutro,Neutro count decreased,increase to Grade 400
WBC,Leukocytosis, increase to Grade 100
WBC,Leukocytosis, increase to Grade 200
WBC,Leukocytosis, increase to Grade 300
WBC,Leukocytosis, increase to Grade 400
WBC,WBC decreased, increase to Grade 100
WBC,WBC decreased, increase to Grade 201
WBC,WBC decreased, increase to Grade 300
WBC,WBC decreased, increase to Grade 400
PrimaryNumber of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline

Urine samples were collected for analysis of blood, glucose, ketones and protein by a dipstick method. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, protein, blood and ketones can be read as negative (-), trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. Any increase means any increase to trace, 1+, 2+ or 3+ post-Baseline relative to Baseline. Number of participants with worst case any increase in urinalysis results post-Baseline relative to Baseline has been presented.

Time frame:
Baseline (Pre-dose, Day 1) and up to Day 126
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline
ParticipantsPlaceboGSK2330811 450 mg
Blood11
Glucose00
Ketones01
Protein12
SecondaryMaximum Plasma Concentration (Cmax) for GSK2330811

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis. Pharmacokinetic Population consisted of all participants in the Safety population who received at least one active dose of study treatment and had at least 1 non-missing PK assessment.

Time frame:
Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Geometric mean · Nanogram per milliliter
Maximum Plasma Concentration (Cmax) for GSK2330811
Nanogram per milliliterGSK2330811 450 mg
Maximum Plasma Concentration (Cmax) for GSK233081163259.308 ± 14.9290
SecondaryArea Under the Plasma Concentration Time-curve From Time Zero to Infinity (AUC[0-infinity]) for GSK2330811

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Geometric mean · Hours*nanogram per milliliter
Area Under the Plasma Concentration Time-curve From Time Zero to Infinity (AUC[0-infinity]) for GSK2330811
Hours*nanogram per milliliterGSK2330811 450 mg
Area Under the Plasma Concentration Time-curve From Time Zero to Infinity (AUC[0-infinity]) for GSK233081145371065.201 ± 22.1925
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2330811

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Geometric mean · Hours*nanogram per milliliter
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2330811
Hours*nanogram per milliliterGSK2330811 450 mg
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) for GSK233081143157791.065 ± 22.8839
SecondaryApparent Systemic Clearance (CL/F) for GSK2330811

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Geometric mean · Liter per hour
Apparent Systemic Clearance (CL/F) for GSK2330811
Liter per hourGSK2330811 450 mg
Apparent Systemic Clearance (CL/F) for GSK23308110.010 ± 22.1925
SecondaryTime to Cmax (Tmax) for GSK2330811

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Median · Hours
Time to Cmax (Tmax) for GSK2330811
HoursGSK2330811 450 mg
Time to Cmax (Tmax) for GSK2330811143.380 (94.82 to 216.25)
SecondaryTerminal Half-life (t1/2) for GSK2330811

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Geometric mean · Hours
Terminal Half-life (t1/2) for GSK2330811
HoursGSK2330811 450 mg
Terminal Half-life (t1/2) for GSK2330811469.117 ± 14.8081
SecondaryApparent Volume of Distribution at Steady State (Vss/F) for GSK2330811

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.

Time frame:
Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution at Steady State (Vss/F) for GSK2330811
LiterGSK2330811 450 mg
Apparent Volume of Distribution at Steady State (Vss/F) for GSK23308116.713 ± 12.2891
SecondaryNumber of Participants With Positive Anti-GSK2330811 Antibodies

Serum samples were analyzed for the presence of anti-GSK2330811 antibodies using an antibody binding assay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Number of participants with confirmed positive anti-GSK2330811 antibodies are presented.

Time frame:
Up to Day 126
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-GSK2330811 Antibodies
ParticipantsPlaceboGSK2330811 450 mg
Number of Participants With Positive Anti-GSK2330811 Antibodies00
SecondaryPlatelet Count Nadir for GSK2330811

Blood samples were collected at indicated time points for analysis of platelet count nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the platelet count.

Time frame:
Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Mean · Giga cells per liter
Platelet Count Nadir for GSK2330811
Giga cells per literPlaceboGSK2330811 450 mg
Platelet Count Nadir for GSK2330811211.5 ± 27.5879.1 ± 29.48
SecondaryTime to Platelet Count Nadir for GSK2330811

Blood samples were collected at indicated time points for analysis of platelet count nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the platelet count. Time to nadir was defined as Study Day of Nadir minus 1.

Time frame:
Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Median · Days
Time to Platelet Count Nadir for GSK2330811
DaysPlaceboGSK2330811 450 mg
Time to Platelet Count Nadir for GSK233081144.0 (4 to 84)20.0 (20 to 26)
SecondaryHemoglobin Nadir for GSK2330811

Blood samples were collected at the indicated time points for analysis of hemoglobin nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the hemoglobin.

Time frame:
Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Mean · Grams per liter
Hemoglobin Nadir for GSK2330811
Grams per literPlaceboGSK2330811 450 mg
Hemoglobin Nadir for GSK2330811136.0 ± 8.49134.9 ± 6.69
SecondaryTime to Hemoglobin Nadir for GSK2330811

Blood samples were collected at indicated time points for analysis of hemoglobin nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the hemoglobin. Time to nadir was defined as Study Day of Nadir minus 1.

Time frame:
Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Reported as:
Median · Days
Time to Hemoglobin Nadir for GSK2330811
DaysPlaceboGSK2330811 450 mg
Time to Hemoglobin Nadir for GSK233081130.5 (20 to 41)55.0 (14 to 125)

Adverse events

Collected over All-cause mortality, SAEs and non SAEs were collected up to Day 126. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/2 (0%)0/2 (0%)2/2 (100%)
GSK2330811 450 mg0/7 (0%)0/7 (0%)6/7 (85.7%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboGSK2330811 450 mg
ThrombocytopeniaBlood and lymphatic system disorders0/25/7
Arthropod biteInjury, poisoning and procedural complications1/20/7
Face injuryInjury, poisoning and procedural complications1/20/7
Injection site painGeneral disorders1/20/7
NasopharyngitisInfections and infestations1/20/7
Oral herpesInfections and infestations1/20/7
Skin lacerationInjury, poisoning and procedural complications0/21/7
Abdominal painGastrointestinal disorders0/21/7
Mouth ulcerationGastrointestinal disorders0/21/7
Injection site bruisingGeneral disorders0/21/7

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboGSK2330811 450 mgTotal
Mean21.0 ± 2.8329.1 ± 6.5227.3 ± 6.76
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGSK2330811 450 mgTotal
Female000
Male279
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboGSK2330811 450 mgTotal
Asian - Japanese Heritage279
08

Study locations

1 site
  • GSK Investigational Site
    London, NW10 7EW, United Kingdom
09

References and documents

Publications

  • Thorsted A, Zecchin C, Berges A, Karlsson MO, Friberg LE. Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis. Clin Pharmacol Ther. 2024 Sep;116(3):703-715. doi: 10.1002/cpt.3246. Epub 2024 Mar 19. PubMed 38501358 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in May 2020, 5 months.

Results were first posted in May 2021, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2019
First posted
Oct 24, 2019
StartActual
Dec 5, 2019
Primary completionActual
May 28, 2020
CompletionActual
May 28, 2020
Results first posted
May 24, 2021
Last update
May 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04138043
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 24, 2019
Start date
Dec 5, 2019
Primary completion
May 28, 2020
Completion
May 28, 2020
Results posted
May 24, 2021
Last update
May 24, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK-2330811

Start the discussion